XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
XTL Biopharmaceuticals Ltd. successfully held its Annual and Extraordinary General Meeting, with shareholders approving all proposals including the appointment of auditors, re-election of board members, and terms of the acquisition of The Social Proxy Ltd. The company, focusing on developing treatments for Lupus and Sjögren’s Syndrome, is traded on both the Nasdaq and Tel Aviv Stock Exchange and is seeking strategic partnerships for clinical trials while expanding its portfolio.
For further insights into XTLB stock, check out TipRanks’ Stock Analysis page.